Software Firm Partners with Kentucky Groups to Launch Transformative Career Planning Platform
Counterpart announces the launch of Futuriti, a digital platform to help Kentuckians of all ages explore and plan their education and career paths.
FRANKFORT, KY, UNITED STATES, February 7, 2025 / EINPresswire.com / -- Counterpart announces the successful development and launch of Futuriti, a groundbreaking digital platform designed to help Kentuckians of all ages explore and plan their education and career paths. Developed in collaboration with the Commonwealth Education Continuum (CEC), Kentucky Council on Postsecondary Education (CPE), Kentucky Center for Statistics (KYSTATS), and the Kentucky Department of Education (KDE), the platform officially launched on Tuesday, February 4, at 10 a.m. in the Capitol Rotunda.
The platform incorporates current, Kentucky-specific education and labor market data to provide users with comprehensive information for making informed decisions about their futures.
'Futuriti is meant not just to be a campaign to encourage higher education, but to be a culture shift that will merge the separation between high school, college, and careers into one systematic approach to building a well-educated Kentucky workforce with increased educational attainment and labor force participation rates that meet or exceed the national average,' said Amanda Ellis, Vice President of Student Access and Success at CPE.
The platform features three primary sections, as well as Future Finder, which helps users explore careers
available in Kentucky offering livable wages that are aligned with their skills and interests:
● Choose Your Career Path: You can use the Futuriti Future Finder to explore careers that suit your skills and interests and learn what credentials you need to qualify. If you don't know where to start, Futuriti also connects you to career quizzes to give you some ideas.
● Continue Your Education: This section showcases Kentucky's diverse educational pathways, from universities and community colleges to technical programs and apprenticeships. It also provides information about and links to financial aid and scholarship resources.
● Start Your Career: This section helps you find jobs once you have the proper education. It includes resume-building tools, interview preparation guides, and direct access to job openings through the Kentucky Career Center's portal.
'Our work is exciting and fulfilling, especially when we partner with teams championing an initiative that will
positively impact so many lives,' Drew Linn, CEO of Counterpart shares.
The launch event is open to the public and will showcase the platform's features through live demonstrations. For more information about Futuriti, visit: https://futuriti.org/.
About Counterpart
Established in 1993 in Indianapolis, Counterpart is a leading custom software development firm dedicated to crafting impactful solutions. With over 200 years of combined experience, the in-house team specializes in web and mobile applications, comprehensive management systems, system integrations, and more. Counterpart works across various industries and technologies, partnering with Fortune 500 companies, non-profits, and small businesses to drive meaningful change in how clients operate and create impact. Learn more at counterpart.biz.
Arianna Cruz
Counterpart
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Integrated Theranostics Solutions and Bridge Oncology Launch Turnkey Theranostics Program to Help Fast-Track Radioligand Therapy Adoption
Strategic partnership brings Nuclear Medicine and Oncology together to advance the future of Theranostics PADUCAH, Ky., June 20, 2025 /PRNewswire/ -- Integrated Theranostics Solutions (ITS) and Bridge Oncology today announced a strategic partnership that brings together two leading consulting service providers to offer the market's only full-service, end-to-end solution for building and scaling theranostics programs. This exclusive collaboration equips private oncology clinics, independent urology practices, academic health systems, and regional networks, looking to enter theranostics, with the operational, clinical, and financial tools needed in one of medicine's fastest growing fields. Healthcare providers used to face months of delays trying to assemble expertise across multiple facets like regulatory compliance protocols, imaging infrastructure, revenue cycle operations and staffing models for theranostics. Many gave up before seeing patient results. "Today, organizations can launch a complete theranostics program with a single partner — from site readiness and clinical workflows to billing optimization and multi-site scaling — without juggling multiple vendors or long timelines," explained Adam Brown, founder of ITS. This comprehensive service offering brings together strong subject matter expertise in Nuclear Medicine, Theranostics, and Radiation Oncology to provide full program execution to help organizations effectively meet the demand to improve patient access to new diagnostic and therapeutic options. These services integrate eight key pillars, which include: Assessment and Strategic Planning Patient Care Coordination Regulatory Compliance Imaging and Equipment Integration Revenue Cycle Management Staffing Solutions Site Design and Readiness Training and Education "With the global Theranostics market projected to grow from $4.3 billion in 2024 to $12.7 billion by 2029,1- healthcare organizations are under increasing pressure to enter the space with confidence and speed," explained Jordan Johnson, CEO of Bridge Oncology. "The need for turnkey, low-risk program development for theranostics treatments has never been greater." "By joining forces, we can deliver a high-quality theranostics program in a financially sustainable way, streamlining reimbursement and cost recovery," Brown continued. "Although these types of programs can be complex, when they are executed well, they can support multi-site expansion, boost the institutional reputation, and support physician recruitment." While every engagement is tailored to a unique, organization-based strategy, the combined service line is intended to bridge the gap between innovation and implementation to accelerate program adoption and revenue generation, providing flexible solutions. "This marks the first time nuclear medicine and radiation oncology have come together to help make theranostics a practical reality," said Dr. Arpit Chhabra, a practicing radiation oncologist and partner in Bridge Oncology. "By integrating diagnostic imaging with targeted therapeutic intervention, we can achieve more accurate tumor characterization and deliver personalized treatment plans that elevate the standard of patient care. Ready to remove the roadblocks in your Theranostics journey? Book a call through our website and let's make it happen. 1Global Theranostics Market to Triple, Reaching $12.7 Billion by 2029." BCC Research, 26 Sept. 2024 For further information, please contact: Adam BrownIntegrated Theranostics SolutionsTime Zone: CST – Central time Tel: 770-715-9892Email: info@ About Integrated Theranostics Solutions Integrated Theranostics Solutions (ITS) is a consulting and management firm dedicated to advancing the field of theranostics. ITS bridges the gap between innovation and implementation, helping healthcare providers, researchers, and industry leaders navigate the complexities of theranostics with strategic insights and tailored solutions. From operational guidance to program development and everything in between, ITS supports the growth and integration of theranostics in clinical and research settings. About Bridge Oncology Bridge Oncology is a healthcare consulting and services company that supports all aspects of oncology care for clinical, financial, and operational excellence. With more than 20 years' experience supporting integrated cancer care practices and community oncology programs, Bridge Oncology is a trusted partner for organizations seeking to improve clinical workflow, create greater operational efficiency, and maximize financial performance. View original content to download multimedia: SOURCE Bridge Oncology Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
5 hours ago
- Forbes
Whiskey Of The Week: Kentucky Owl Batch #13 Bourbon
Kentucky Owl has a weird, possibly unique story in the annals of whiskey history. The brand's history dates back to 1879, when it was founded by Charles M. Dedman and awarded license DSP-16 to produce distilled spirits. By all accounts the distillery was a successful one, lasting until Prohibition fever started sweeping the nation in the second decade of the 20th century. According to lore, Kentucky Owl ceased production in 1916 (three years before Prohibition became law in Kentucky and four years before it went into effect nationwide) and several thousand barrels of whiskey were put into a federally controlled warehouse. Shortly thereafter, a suspicious fire either destroyed the whiskey or liberated it for use in the nascent bootlegging industry, depending on who you ask. Fast forward almost a century, to 2014, when Dedman's great-great grandson, Dixon Dedman, decided to revive the Kentucky Owl name. Using sourced whiskeys this time, he created a blended bourbon in a classy bottle that sold for eye-popping prices — $170 for a blend sourced from unnamed distilleries was a lot less common a decade ago than it is today. And it was an immediate hit, with each batch selling out almost instantly. In 2017, Dedman released the first Kentucky Owl rye, and the same year sold the brand to Stoli Group. Kentucky Bourbon Hall of Famer John Rhea rides off into the sunset with a terrific, if expensive, blend. Photo courtesy Stoli Group The plan was for Dedman to stay on as blender and frontman, but business differences soon reared their ugly head. By 2021 he was out; nowadays he's back blending his 2XO brand. At the same time, Stoli Group was stumbling, eventually filing for bankruptcy in 2024. Kentucky Owl, loosed from its historical connection to its founder, endures, though it's been a mixed bag in the Stoli era, with excellent additions to the permanent range like Confiscated bourbon constrasted with head-scratchers like the St. Patrick's Edition. It also spawned The Wiseman, an inexpensive, relatively satisfying spinoff brand. Longtime Four Roses distillery COO and Kentucky Bourbon Hall of Fame inductee John Rhea took the blending reins from Dedman in 2021, and the Batch series of limited edition blends continued to draw rave reviews on his watch, even as the suggested retail price rose to $400 (bottles can be found for less — and more — if you search online). If it's any consolation to your wallet, the new Kentucky Owl Batch #13 Bourbon may at least wind up being a collector's item, because it's John Rhea's final blend before retiring after almost half a century in the whiskey biz. He can ride off into the sunset knowing he's going out on a high note — it's been a while since I tried one of the Batches, but Lucky 13 is as good as any I've tasted. Batch #13 is a blend of high-rye and wheated bourbons sourced, as always, from unnamed distilleries — mostly 8-9 years old, along with some 4, 5, and 6 in the mix. Bottled at a cask strength of 56.8% ABV, it's rich and intense on the palate, with desserty chocolate and caramel notes overlaid with candied orange peel. Oak and peppery tannins show up midpalate and linger on the finish along with gooey, fudgy chocolate. It's a sophisticated, well-balanced sipper that also appeals to my sweet tooth. As with all the Kentucky Owl Batches, #13 is a limited edition, though just how limited isn't known. As of this writing it's available through ReserveBar and soon to arrive on Flaviar, with bottles going to select brick-and-mortar retailers throughout the U.S. as well. Based on the continued availability of some earlier Batches, I wouldn't necessarily recommend sprinting with a fistful of bills to your local liquor emporium this very instant. But should a bottle cross your path, it'd be wise to make room on the shelf for it.
Yahoo
a day ago
- Yahoo
KFC's parent company Yum! Brands names new CEO
KFC's parent company, Yum! Brands has appointed Chris Turner as its new CEO from 1 October 2025. Turner will take over the role from David Gibbs, who plans to retire after a 37-year tenure with the brand. Gibbs will continue as the brand's adviser until the end of 2026. Since 2019, Turner has been the chief financial officer at Yum! Brands. In 2024, his position grew to encompass the role of chief franchise officer. His duties included overseeing finance, corporate strategy, the supply chain, maintaining franchise standards and providing support. Turner has been pivotal in advancing the brand's strategic initiatives, especially in the digital and technology arenas. His leadership saw the launch of the Byte by Yum! AI-driven restaurant technology platform, and the Saucy by KFC concept. Turner also led the creation of a global supply chain centre of excellence. His responsibilities will include fostering the Good Growth strategy, which encompasses digital initiatives and scaling new ideas to enhance the company's leading brands. Turner stated: 'I want to sincerely thank David Gibbs for his exceptional leadership and partnership. 'I'm excited to build on all that we've accomplished together alongside our talented teams and in partnership with our franchisees around the world, as we innovate, grow our brands, and continue delivering exceptional experiences for our consumers.' Yum! Brands is headquartered in the US state of Kentucky and operates 61,000 restaurants in 155 countries under the Taco Bell, Pizza Hut, Habit Burger & Grill and KFC concepts. For the first quarter of the fiscal year 2025, which ended 31 March, Yum! Brands reported 5% growth in its worldwide system sales, excluding the impact of foreign currency translation. "KFC's parent company Yum! Brands names new CEO" was originally created and published by Verdict Food Service, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
